ARKG
ETF
Genomics
NYSEARCA
ARK Genomic Revolution ETF
$44.02
+0.57 (+1.31%)
Fund Overview
by ARK Invest
Actively managed fund focused on the genomic revolution: gene editing (CRISPR), molecular diagnostics, targeted therapeutics, stem cells, and agricultural biology. High-conviction positions in companies reshaping medicine.
AUM$1.8B
Expense Ratio0.75%
Holdings35
Dividend Yield0.0%
DistributionAnnually
BenchmarkNone (Active)
InceptionOct 2014
ExchangeNYSEARCA
Price Data
Open$43.13
Prev Close$43.45
Day Range$42.91 — $44.19
52W Range$17.55 — $34.37
52-Week Range
$17.55
$34.37
From 52W High
28.1%
From 52W Low
+150.8%
Genomics ETF Comparison
Top Genomics Stocks
View all →
| Stock | Price | Change | Market Cap |
|---|---|---|---|
| ABBV | $261.83 | -1.56% | 443.23B |
| AMGN | $433.73 | -1.95% | 225.90B |
| GILD | $143.44 | -2.82% | 169.87B |
| VRTX | $540.26 | -2.14% | 135.24B |
| REGN | $826.64 | -1.69% | 82.16B |
| NTRA | $324.84 | -0.07% | 44.64B |
| RVMD | $211.74 | -1.36% | 43.21B |
| BIIB | $214.35 | -3.25% | 31.05B |
| ALNY | $229.30 | -5.49% | 30.39B |
| INSM | $125.08 | -4.27% | 28.45B |
ARKG FAQ
What is ARKG?
ARKG is the ARK Genomic Revolution ETF, an exchange-traded fund managed by ARK Invest. It tracks the None (Active) and holds 35 Genomics securities with an expense ratio of 0.75%.
What is the expense ratio of ARKG?
ARKG charges an annual expense ratio of 0.75%, which means you pay $75.00 per year for every $10,000 invested. This fee is deducted automatically from the fund's returns.
Explore Genomics Stocks
View our full list of individual genomics stocks with prices, fundamentals, and analyst ratings.
Last updated: Aug 17, 2026 at 5:00 PM ET